雪榕生物(300511) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥575,916,010.18, representing a 1.66% increase compared to ¥566,499,913.52 in the same period last year[3] - Net profit attributable to shareholders decreased by 43.38% to ¥57,397,068.93 from ¥101,367,147.34 year-on-year[3] - Basic earnings per share fell by 45.83% to ¥0.13, compared to ¥0.24 in the same period last year[3] - The total comprehensive income for Q1 2022 was ¥60,304,994.90, down from ¥93,107,824.21 in the same period last year, indicating a decrease of about 35.3%[23] - Net profit for the quarter was CNY 60,526,964.61, compared to CNY 96,052,419.32 in the same period last year, reflecting a decrease[22] Cash Flow - The net cash flow from operating activities dropped by 61.55% to ¥36,207,316.24, down from ¥94,171,489.26 in the previous year[3] - Cash inflows from operating activities totaled ¥567,609,702.47, slightly up from ¥566,819,501.52 in the previous year, showing a marginal increase of 0.14%[26] - Cash flow from investing activities resulted in a net outflow of ¥102,660,123.39, an improvement from a net outflow of ¥314,263,474.03 in the previous year[27] - Cash flow from financing activities generated a net inflow of ¥435,119,938.32, compared to a net outflow of ¥83,470,634.71 in Q1 2021, indicating a significant turnaround[27] Assets and Liabilities - Total assets increased by 4.56% to ¥4,747,152,356.00 from ¥4,539,961,256.98 at the end of the previous year[3] - Total liabilities decreased slightly to CNY 2,642,700,976.17 from CNY 2,685,582,068.16[19] - The company's equity attributable to shareholders increased to CNY 2,118,878,936.05 from CNY 1,672,047,546.39, reflecting a growth of 26.73%[19] - Long-term borrowings rose to CNY 520,547,357.44 from CNY 392,496,781.30, an increase of 32.66%[19] Shareholder Information - The company issued a total of 65,676,567 shares of ordinary stock to 11 specific investors, which were listed on the Shenzhen Stock Exchange on March 21, 2022[15] - The total number of restricted shares at the beginning of the period was 106,622,182, with 4,311,302 shares released from restriction during the period[14] - The company has 80,523,787 restricted shares held by Yang Yongping, which are locked due to executive restrictions[13] - The top 10 unrestricted shareholders hold a total of 80,523,787 shares, with Yang Yongping and Zhejiang Yinwan Stere Investment Management Co., Ltd. being the largest shareholders[12] Research and Development - Research and development expenses decreased by 61.62% to ¥1,826,764.99, primarily due to the shutdown of the Shanghai base[6] - The company has not reported any new product launches or technological advancements in this quarter[16] Other Income and Expenses - Other income related to government subsidies decreased by 51.82% to ¥6,462,755.79 compared to the previous year[7] - The company reported a decrease in other comprehensive income attributable to the parent company, with a net amount of -¥133,181.83 compared to -¥1,906,383.46 in the previous year[23] Audit Information - The company did not conduct an audit for the Q1 2022 report[28]